Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of RO7062931 in Healthy Volunteers and Chronic Hepatitis B
NCT03038113Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2017
- Primary completion
- Oct 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of RO7062931 in Chronic Hepatitis B (CHB), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events at Day 113, Percentage of Participants With Laboratory Abnormalities at Day 113 and 2 more. Started Feb 2017; status: completed.
02
Drugs
RO7062931
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03038113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038113.